CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
前列腺癌免疫治疗：是时候超越检查点抑制剂
英文原题：Prostate Cancer Immunotherapy: Time to Move Beyond Checkpoint Inhibitors.
查看英文原题
Prostate Cancer Immunotherapy: Time to Move Beyond Checkpoint Inhibitors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
免疫检查点抑制剂（ICI）推动了癌症免疫治疗的发展，在许多癌症中疗效显著。在ICI出现之前，前列腺癌是最早获批使用癌症免疫疗法的疾病之一，治疗方法是抗癌疫苗sipleucel-T。尽管早期取得成功，ICI此后未能改善大多数前列腺癌患者的结局，形成了前列腺癌对免疫疗法耐受的观点。CAR-T 细胞、双特异性抗体疗法、抗癌疫苗和细胞因子疗法等新疗法，正在提供早期证据，显示前列腺癌肿瘤免疫微环境可通过检查点抑制以外的方式进行调节。尤其值得注意的是，靶向STEAP-1和KLK2等肿瘤抗原的双特异性T细胞衔接器（BiTE）临床试验显示出临床潜力。超越ICI可能为改变前列腺癌肿瘤免疫微环境和改善临床结局带来新方法。
展开英文摘要原文
Immune checkpoint inhibitors (ICIs) have led the advancement of cancer immunotherapy, with remarkable efficacy in many cancers. Prior to the advent of ICIs, prostate cancer had one of the first approvals for cancer immunotherapy with sipleucel-T, an anti-cancer vaccine. Despite this early success, ICIs have since failed to improve outcomes for most patients with prostate cancer, generating a narrative that prostate cancer is resistant immunotherapeutic approaches.
Novel therapies like CAR T-cells, bispecific antibody therapies, anti-cancer vaccines and cytokine therapies are now generating early evidence for how the prostate cancer tumor immune microenvironment can be manipulated beyond checkpoint inhibition. Most notably, clinical trials with bispecific T-cell engagers (BiTEs) targeting tumor antigens like STEAP-1 and KLK2 have shown clinical promise. Moving beyond ICIs may lead to new approaches to alter the prostate cancer tumor immune microenvironment and improve clinical outcomes.
论文信息
- 作者
- Abel M、Warner AB、Karzai F、Madan RA
- 单位
- Genitourinary Malignancies Branch, Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA.United States
- 文献类型
- 综述
- 期刊
- ImmunoTargets and therapy2025
- 原文标识
- PubMed 40970252 · DOI 10.2147/ITT.S549873
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →